67 related articles for article (PubMed ID: 33909100)
1. Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer.
Mori K; Sasaki H; Tsutsumi Y; Sato S; Takiguchi Y; Saito S; Nishi E; Ishii G; Yamamoto T; Koike Y; Miki J; Shimomura T; Kimura T; Miki K; Shariat SF; Takahashi H; Aoki M; Egawa S
Strahlenther Onkol; 2021 Nov; 197(11):976-985. PubMed ID: 33909100
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation.
Kadena S; Urabe F; Iwatani K; Suzuki H; Imai Y; Tashiro K; Tsuzuki S; Honda M; Koike Y; Shimomura T; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
Int J Clin Oncol; 2023 Aug; 28(8):1092-1100. PubMed ID: 37227547
[TBL] [Abstract][Full Text] [Related]
3. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).
Yorozu A; Namiki M; Saito S; Egawa S; Yaegashi H; Konaka H; Momma T; Fukagai T; Tanaka N; Ohashi T; Takahashi H; Nakagawa Y; Kikuchi T; Mizokami A; Stone NN
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):390-401. PubMed ID: 37802225
[TBL] [Abstract][Full Text] [Related]
4. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
Roy S; Romero T; Michalski JM; Feng FY; Efstathiou JA; Lawton CAF; Bolla M; Maingon P; de Reijke T; Joseph D; Ong WL; Sydes MR; Dearnaley DP; Tree AC; Carrier N; Nabid A; Souhami L; Incrocci L; Heemsbergen WD; Pos FJ; Zapatero A; Guerrero A; Alvarez A; San-Segundo CG; Maldonado X; Reiter RE; Rettig MB; Nickols NG; Steinberg ML; Valle LF; Ma TM; Farrell MJ; Neilsen BK; Juarez JE; Deng J; Vangala S; Avril N; Jia AY; Zaorsky NG; Sun Y; Spratt D; Kishan AU;
J Clin Oncol; 2023 Nov; 41(32):5005-5014. PubMed ID: 37639648
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis.
Miyajima K; Sato S; Uchida N; Suzuki H; Iwatani K; Imai Y; Aikawa K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Honda M; Koike Y; Miki J; Miki K; Shimomura T; Yuen S; Yamada Y; Aoki M; Takahashi H; Urabe F; Kimura T
Clin Genitourin Cancer; 2024 Apr; 22(2):149-156.e1. PubMed ID: 38007354
[TBL] [Abstract][Full Text] [Related]
6. LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients.
Boehle A; Zywietz D; Robrahn-Nitschke I; Lusch A; König IR
Urol Oncol; 2023 Nov; 41(11):454.e17-454.e24. PubMed ID: 37714724
[TBL] [Abstract][Full Text] [Related]
7. Proton therapy for the management of localized prostate cancer: Long-term clinical outcomes at a comprehensive cancer center.
Sosa AJ; Thames HD; Sanders JW; Choi SL; Nguyen QN; Mok H; Ron Zhu X; Shah S; Mayo LL; Hoffman KE; Tang C; Lee AK; Pugh TJ; Kudchadker R; Frank SJ
Radiother Oncol; 2023 Nov; 188():109854. PubMed ID: 37597805
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Significance of Selected HLA Alleles on Prostate Cancer Outcome.
Stokidis S; Baxevanis CN; Fortis SP
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833904
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported lower limb edema after primary radiotherapy for prostate cancer.
Fokdal L; Berg M; Zedan AH; Mortensen B; Nissen HD; Bentzen L; Svenson M; Madsen CV
Acta Oncol; 2023 Oct; 62(10):1279-1285. PubMed ID: 37647364
[TBL] [Abstract][Full Text] [Related]
10. Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment.
Zharinov GM; Bogomolov OA; Chepurnaya IV; Neklasova NY; Anisimov VN
Oncotarget; 2020 Oct; 11(41):3723-3729. PubMed ID: 33110479
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of PSA bounce in prostate cancer following definitive radiation therapy: a systematic review and meta-analysis.
Urabe F; Kimura S; Tashiro K; Kido M; Sasaki H; Aoki M; Kimura T; Miki K; Egawa S
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):976-985. PubMed ID: 33947976
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy.
Yamazaki H; Suzuki G; Masui K; Aibe N; Shimizu D; Kimoto T; Yoshida K; Nakamura S; Okabe H
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33924563
[TBL] [Abstract][Full Text] [Related]
13. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer.
Ito M; Sasamura K; Takase Y; Kotsuma T; Oshima Y; Minami Y; Suzuki J; Tanaka E; Ohashi W; Oguchi M; Okuda T; Suzuki K; Yoshioka Y
Anticancer Res; 2021 May; 41(5):2523-2531. PubMed ID: 33952480
[TBL] [Abstract][Full Text] [Related]
15. Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy.
Rajwa P; Schuettfort VM; Quhal F; Mori K; Katayama S; Laukhtina E; Pradere B; Motlagh RS; Mostafaei H; Grossmann NC; Aulitzky A; Paradysz A; Karakiewicz PI; Fajkovic H; Zimmermann K; Heidenreich A; Gontero P; Shariat SF
World J Urol; 2021 Oct; 39(10):3771-3779. PubMed ID: 33997919
[TBL] [Abstract][Full Text] [Related]
16. Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer.
Shiota M; Akamatsu S; Narita S; Terada N; Fujimoto N; Eto M
JMA J; 2021 Apr; 4(2):99-111. PubMed ID: 33997443
[TBL] [Abstract][Full Text] [Related]
17. Urinary extracellular vesicles: a rising star in bladder cancer management.
Urabe F; Kimura T; Ito K; Yamamoto Y; Tsuzuki S; Miki J; Ochiya T; Egawa S
Transl Androl Urol; 2021 Apr; 10(4):1878-1889. PubMed ID: 33968676
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1.
Zimmermann K; Mostafaei H; Heidenreich A; Schmelz HU; Shariat SF; Mori K
Curr Opin Urol; 2021 Jul; 31(4):297-303. PubMed ID: 33965980
[TBL] [Abstract][Full Text] [Related]
19. Association between male infertility and prostate cancer: a systematic review and meta-analysis.
Laukhtina E; Mori K; Pradere B; Shariat SF
Curr Opin Urol; 2021 Jul; 31(4):346-353. PubMed ID: 33965979
[TBL] [Abstract][Full Text] [Related]
20.
Jiao D; Zhou X; Yao Y; Chen J; Lei Q; Ren J; Han X
Am J Cancer Res; 2021; 11(4):1321-1334. PubMed ID: 33948360
[No Abstract] [Full Text] [Related]
[Next] [New Search]
